These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20492889)

  • 1. [Temporary interruption of treatment with etanercept].
    Ruiz-Genao DP; López-Estebaranz JL
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():102-5. PubMed ID: 20492889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intermittent use of etanercept in psoriasis].
    Herrera E; Alcaide AJ
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():18-25. PubMed ID: 20492876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].
    Wozel G
    Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
    Safa G; Loppin M; Bousser AM; Barbarot S
    J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.
    Esposito M; Gisondi P; Cassano N; Babino G; Cannizzaro MV; Ferrucci G; Chimenti S; Giunta A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S31-4. PubMed ID: 25381971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
    Saraceno R; Scotto G; Chiricozzi A; Chimenti S
    Acta Derm Venereol; 2009; 89(4):412-3. PubMed ID: 19688158
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
    Krell JM
    J Am Acad Dermatol; 2006 Jun; 54(6):1099-101. PubMed ID: 16713481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.
    Strohal R; Chimenti S; Vena GA; Girolomoni G
    J Dermatolog Treat; 2013 Jun; 24(3):199-208. PubMed ID: 22812568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
    Strohal R; Puig L; Chouela E; Tsai TF; Melin J; Freundlich B; Molta CT; Fuiman J; Pedersen R; Robertson D
    J Dermatolog Treat; 2013 Jun; 24(3):169-78. PubMed ID: 22251226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
    Saraceno R; Pietroleonardo L; Mazzotta A; Zangrilli A; Bianchi L; Chimenti S
    Expert Opin Biol Ther; 2013 Apr; 13(4):469-73. PubMed ID: 23157654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.
    Gilbert KE; Manalo IF; Wu JJ
    J Am Acad Dermatol; 2015 Aug; 73(2):329-31. PubMed ID: 26183982
    [No Abstract]   [Full Text] [Related]  

  • 13. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
    Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
    J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of etanercept in the treatment of psoriasis and psoriatic arthritis.
    Fuchs BS; Hadi S
    Rev Recent Clin Trials; 2006 Sep; 1(3):259-63. PubMed ID: 18473978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etanercept in pregnancy and breast-feeding].
    Borrego L
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():97-101. PubMed ID: 20492888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etanercept in childhood psoriasis].
    Pérez-Barrio S; Careaga JM
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():50-4. PubMed ID: 20492881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.